Authorized purpose: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
Clinical role
Automated clip selection and left-ventricular ejection-fraction estimation for clinician review.
Images and patients
Ultrasound · Heart; left ventricle; adult cardiac evaluation
Key limitation
Keep in mind: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart; left ventricle; adult cardiac evaluation Input: Previously acquired adult transthoracic cardiac ultrasound images from supported apical four-chamber, apical two-chamber, or parasternal long-axis views.
Who uses it?Intended users: Clinicians and trained echocardiography professionals performing adult cardiac evaluation.
What does the software produce?Output: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.
What is its most important limitation?Key limitation: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
Clinical takeaway. Clinical role: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Specifically, software verification was conducted at unit, module, and system integration levels." … "A Clip Annotator study verified the ability of the software to receive, annotate and select clips for interpretation by the AutoEF Calculation Service. Results of the Clip Annotator were compared to evaluation by a panel of expert readers.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Specifically, software verification was conducted at unit, module, and system integration levels." … "A Clip Annotator study verified the ability of the software to receive, annotate and select clips for interpretation by the AutoEF Calculation Service. Results of the Clip Annotator were compared to evaluation by a panel of expert readers.". Read from the exact FDA decision document on 2026-11-14.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Clip Annotator positive predictive value
0.97 proportion lower bound
EndpointObserved PPV point estimate across imaging modes and views
PopulationClip Annotator study compared with expert readers
Tested versionCaption Interpretation Automated Ejection Fraction Software configuration described in K200621
K200621 FDA evidence package for Caption Interpretation Automated Ejection Fraction Software
DesignFDA 510(k) Clip Annotator study and pivotal clinical investigation comparing AutoEF to conventional ejection-fraction calculation methods.
PopulationHeart; left ventricle; adult cardiac evaluation
Scopeexact submission
Tested versionCaption Interpretation Automated Ejection Fraction Software configuration described in K200621
IndependenceSponsor or vendor study
K200621
The FDA summary reports thresholded PPV and sensitivity point estimates and qualitative statements about RMSD acceptance criteria, but does not expose all study counts in the public decision material.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
1 exact-submission FDA recall record matched K200621 in the 2026-09-02 openFDA snapshot. Confirm affected model, version, units, correction, and current manufacturer instructions locally. FDA recall Z-2111-2021 affected Caption AI version 1.2.0. Unintended video frames could produce incorrect automated ejection-fraction and image-quality-score estimates. FDA lists the recall as terminated.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Previously acquired adult transthoracic cardiac ultrasound images from supported apical four-chamber, apical two-chamber, or parasternal long-axis views.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own press release announces the acquisition of Caption Health, Inc., and Caption AI is sold as a GE HealthCare product (Vscan Air Caption AI page on gehealthcare.com). Corporate program statement; portal content is credentialed; exact-release scope is not established.
Only clinicians and trained echocardiography professionals performing adult cardiac evaluation should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K200621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.
The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K200621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. automated echocardiography ejection-fraction software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The locked snapshot contains no PubMed or ClinicalTrials.gov candidates for K200621; no evidence was promoted or quarantined. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Authorized purpose: Provides AI-assisted cardiac, lung and abdominal quality feedback and measurements; users remain responsible for scan quality and diagnosis and must not rely solely on the software.
Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.